Australia markets closed

Incannex Healthcare Limited (IHL.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.27000.0000 (0.00%)
At close: 04:10PM AEST
Full screen
Previous close0.2700
Bid0.2700 x 19574500
Ask0.2750 x 30420000
Day's range0.2700 - 0.2800
52-week range0.1850 - 0.7550
Avg. volume3,648,614
Market cap346.229M
Beta (5Y monthly)2.47
PE ratio (TTM)N/A
EPS (TTM)-0.0120
Earnings date29 Aug 2022 - 02 Sept 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Simply Wall St.

    Do Institutions Own Incannex Healthcare Limited (ASX:IHL) Shares?

    The big shareholder groups in Incannex Healthcare Limited ( ASX:IHL ) have power over the company. Large companies...

  • PR Newswire

    Incannex Engages Curia to Scale-up Manufacture of cGMP IHL-216A

    Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that it has engaged Curia Global, Inc. ('Curia') to further develop and manufacture GMP-grade IHL-216A, Incannex's proprietary inhaled drug product for the treatment of concussion and traumatic brain injury ('TBI').

  • PR Newswire

    Incannex Healthcare Quarterly Activities Report and Appendix 4C Cash Flow Statement

    Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL), ('Incannex' or the 'Company'), is pleased to provide its quarterly activities report and appendix 4C for the period ended 30 June 2022. Incannex is undertaking a multitude of U.S. Food and Drug Administration ('FDA') programs for cannabinoid pharmaceutical products and psychedelic medicine therapies administered by health professionals.